Drug Profile
Research programme: nicotinamide phosphoribosyltransferase inhibitors - Valerio Therapeutics
Alternative Names: TP 201565Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator TopoTarget
- Developer Valerio Therapeutics
- Class Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2014 Discontinued - Preclinical for Cancer in Denmark (Parenteral)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 22 Apr 2009 Preclinical trials in Cancer in Denmark (Parenteral)